Hadoux et al. generated a patient-derived iPSCs carrying the RET mutation along with the CRISPR/Cas9-corrected isogenic control to unravel the molecular mechanisms underlying the multiple endocrine neoplasia type 2A [40]. The gene discussed is RET; the disease is multiple endocrine neoplasia type 2.